Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma

Figure 6 miR-135a-5p enhanced Dox-resistance and reduced cell apoptosis of hepatocellular carcinoma cells by down-regulating vesicle-associated membrane protein 2. A: The apoptosis rate of HepG2 cells after treatment with Doxorubicin hydrochloride (Dox). Flow cytometry was used to detected the effect of HepG2 cells with overexpressed miR-135a-5p after treatment with Dox; B: Annexin V-FITC/PI assay was used to discover the rate of apoptosis in HepG2 cells cultured with mimic-loaded exosomes; C and D: Flow cytometry was used to detect the rate of Dox-induced apoptosis in HepG2 cells after transfected with the plasmid group shown in the figure above; E and F: Cell counting kit 8 assay was used to determine the proliferation rate of HepG2 cells transfected with miR-135a-5p mimics after treated with Dox; G and H: Cell counting assay was performed to determine the proliferation of HepG2 cells transfected with pcDNA3.1-vesicle-associated membrane protein 2. ^aP < 0.05; ^bP < 0.01. Dox: Doxorubicin hydrochloride; VAMP2: Vesicle-associated membrane protein 2.